NeuroOne Medical Technologies Hits 52-Week Low at $2.04 Amid Financial Struggles

NeuroOne Medical Technologies Corp., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 2.04 on July 21, 2026. This significant decline highlights ongoing challenges for the company, which has seen its stock price drop considerably from its 52-week high of USD 6.96. Despite a notable one-year performance increase of 138.34%, NeuroOne's recent financial metrics reveal underlying issues. The company reported a net sales figure of USD 1.86 million for the most recent quarter, reflecting a decline of 14.55%. Additionally, the debt-equity ratio stands at -0.54, indicating a precarious financial position, while the return on equity is notably low at -116.32%. With a market capitalization of USD 37 million, NeuroOne's stock is trading at a price-to-book ratio of 5.81, which suggests that investors are currently valuing the company at a premium relative to its book value. The company has not paid dividends, and its financial performance has consistently underperformed against the S&P 500 over the past three years.